Jack Sloane
Senior Principal Scientist Bristol Myers Squibb
Seminars
Wednesday 21st October 2026
Unlocking Novel Covalent Reactivity in KRAS G12C Through Innovative Warhead Design
2:00 pm
- Exploring a “warhead-first” approach to covalent inhibitor design beyond traditional binder optimization strategies
- Leveraging novel reactive chemistries and molecular trajectories to uniquely engage on-form KRAS G12C selectivity
- Linker geometry, electrophilicity and heterocycle basicity jointly govern covalent potency against on-form KRAS G12C
